Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

The combination of daratumumab (Darzalex), ixazomib (Ninlaro), and dexamethasone showed promising results when administered to patients with relapsed/refractory multiple myeloma who had previously received lenalidomide (Revlimid) treatment. These phase 2 DARIA trial results were presented at EHA23 and again in this MEDtalk by Professor Evangelos Terpos from the National and Kapodistrian University of Athens in Greece.